相关实验视频

Updated: Jul 12, 2025

Preparation and Characterization of Nanoliposomes for the Entrapment of Bioactive Hydrophilic Globular Proteins

Preparation and Characterization of Nanoliposomes for the Entrapment of Bioactive Hydrophilic Globular Proteins

Published on: August 31, 2019

微凝中的酸胺功能化脂质体,用于输送基尼斯坦,有效治疗性结肠炎

Huijia Yan¹, Yanfei Li¹, Sihui Li¹

¹Research Group of Nutrition and Health, National Engineering Research Center of Seafood, Dalian Polytechnic University, Dalian 116034, China. hujiangning2005@hotmail.com.

Journal of materials chemistry. B

|October 25, 2023

概括

一种新的微凝输送系统有效地准结肠,释放天然化合物基因斯坦来治疗性结肠炎 (UC). 这种方法可以改善药物输送并减少炎症,为UC患者提供有前途的口服治疗.

科学领域:

生物材料科学生物材料科学
药物输送系统药物输送系统
胃肠病学胃肠病学

背景情况:

性结肠炎 (UC) 治疗面临的局限性包括吸收不良和非特异性药物释放.
有针对性的输送系统是有效的结肠药物输送和UC治疗中受控释放所需的.

研究的目的:

开发一种新的微凝口服输送系统,用于针对性地向结肠输送Genistein (Gen),以治疗性结肠炎 (UC).
通过将其封装在脂质体纳米颗粒和酸盐微凝中来增强基因斯坦的治疗疗效.

主要方法:

基因斯坦被装入了脂酶功能化脂质体纳米颗粒 (Gen@Li NPs).
使用电喷技术 (Gen@Li微凝) 将Gen@Li NP封装成酸盐微凝.
在体外和体外研究评估了DSS诱导的UC小鼠模型中的向,细胞吸收,结肠保留,药物释放和治疗效果.

主要成果:

基因@Li NPs展示了高效的巨细胞向和细胞内部化.
与Gen@Li NP相比,Gen@Li微凝显示出长时间的结肠保留和受控释放.
Gen@Li微凝通过减少促炎性细胞因子和促进粘膜屏障修复,显著缓解了UC症状.

结论:

开发的Gen@Li微凝系统为UC治疗提供了针对性和受控的基因斯坦到结肠的输送.
这种新的口服输送系统显示了改善天然化合物的治疗结果的潜力,用于治疗性结肠炎.

更多相关视频

Preparation, Administration, and Assessment of In Vivo Tissue-Specific Cellular Uptake of Fluorescent Dye-Labeled Liposomes

Preparation, Administration, and Assessment of In Vivo Tissue-Specific Cellular Uptake of Fluorescent Dye-Labeled Liposomes

Published on: July 30, 2020

A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles

A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles

Published on: December 23, 2016

相关概念视频

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...